|
| 36030128 | Impact of the COVID-19 pandemic on antiviral drug development for other community-acquired respiratory viruses' infections. | Therapie | 2023 |
| 37002477 | Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape. | Leukemia | 2023 |
| 37433887 | Clinical features and genomic landscape of myeloproliferative neoplasm (MPN) patients with autoimmune and inflammatory diseases (AID). | Leukemia | 2023 |
| 34895756 | The challenge of targets and drug discovery using large-scale screening approaches in onco-hematology. | Therapie | 2022 |
| 35405016 | Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts. | Cancer Discov | 2022 |
| 35668193 | P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia. | Nat Cancer | 2022 |
| 36379921 | Breakthrough infections in MPN-COVID vaccinated patients. | Blood Cancer J | 2022 |
| 35064223 | Second versus first wave of COVID-19 in patients with MPN. | Leukemia | 2022 |
| 33414483 | High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. | Leukemia | 2021 |
| 33765419 | Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. | Lancet Haematol | 2021 |
| 33790022 | Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. | Sci Transl Med | 2021 |
| 33623140 | Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease. | Leukemia | 2021 |
| 33670178 | Descriptive and Functional Genomics in Acute Myeloid Leukemia (AML): Paving the Road for a Cure. | Cancers (Basel) | 2021 |
| 33563901 | Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. | Blood Cancer J | 2021 |
| 34063894 | Systemic Treatment Initiation in Classical and Endemic Kaposi's Sarcoma: Risk Factors and Global Multi-State Modelling in a Monocentric Cohort Study. | Cancers (Basel) | 2021 |
| 34135309 | Long-term follow-up of recovered MPN patients with COVID-19. | Blood Cancer J | 2021 |
| 32826232 | The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. | Cancer Discov | 2020 |
| 30390009 | Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML. | Leukemia | 2019 |
| 28597151 | Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials. | Invest New Drugs | 2018 |
| 29515000 | Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. | Sci Transl Med | 2018 |
| 28191887 | The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. | Nat Med | 2017 |
| 28225458 | Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system. | Anticancer Drugs | 2017 |
| 25573976 | HLA-matched related-donor HSCT in Fanconi anemia patients conditioned with cyclophosphamide and fludarabine. | Blood | 2015 |
| 26496242 | Evaluation of Improved Glycogen Synthase Kinase-3α Inhibitors in Models of Acute Myeloid Leukemia. | J Med Chem | 2015 |
| 24665349 | Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation. | J Cancer | 2014 |
| 23558525 | Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma. | Leukemia | 2013 |
| 22689802 | Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone. | J Clin Oncol | 2012 |
| 21047972 | Rare melanocortin-3 receptor mutations with in vitro functional consequences are associated with human obesity. | Hum Mol Genet | 2011 |
| 19350673 | TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. | Ann Neurol | 2009 |